{"meshTags":["Fusion Proteins, bcr-abl","Mutation","Antineoplastic Agents","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Imidazoles","Drug Resistance, Neoplasm","Pyridazines","Protein Kinase Inhibitors","Humans"],"meshMinor":["Fusion Proteins, bcr-abl","Mutation","Antineoplastic Agents","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Imidazoles","Drug Resistance, Neoplasm","Pyridazines","Protein Kinase Inhibitors","Humans"],"genes":["BCR","ABL1","BCR","ABL1"],"publicationTypes":["Comment","Journal Article"],"abstract":"BCR-ABL1 compound mutations harboring T315I are resistant to multiple TKIs, including ponatinib. ","title":"BCR-ABL1 compound mutations drive ponatinib resistance.","pubmedId":"25367954"}